INS and type 1 diabetes mellitus: TNF-α blocking agents have demonstrated efficacy in preserving insulin secretion in new onset type 1 diabetes; initially in a pilot study of etanercept [18] and more recently, in a phase 1/2 clinical trial of golimumab [19, 20].